13 2024.12

2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

10 2024.11

"Dual Target": Telitacicept Offers New Hopes for Patients with B-Cell-Mediated Autoimmune Disorders

27 2024.10

Priority Review Granted to BLA of RemeGen’s Telitacicept for Its Third Indication of Myasthenia Gravis

17 2024.10

IGCS 2024 | Results of Disitamab Vedotin Combined with Cadonilimab for Cervical Cancer First Announced with ORR up to 50%

15 2024.10

BLA Accepted and Priority Review Granted to Disitamab Vedotin for Its Third Indication of HER2-Positive Advanced Breast Cancer with Liver Metastasis

27 2024.09

2024 CSCO｜Disitamab Vedotin Combined with Camrelizumab and S-1 as Perioperative Therapy for Gastric Cancer Showed Promising Efficacy with a pCR Rate of 30%

15 2024.09

2024 ESMO | Disitamab Vedotin Achieves 33 Months OS as First-Line Treatment of Advanced Urothelial Carcinoma

14 2024.08

Enrollment Completed in Phase 3 Clinical Study of Disitamab Vedotin Combined with PD-1 Inhibitor as First-Line Treatment for Advanced Urothelial Carcinoma

13 2024.08

BLA on Agenda: A Phase III Trial on Telitacicept for Myasthenia Gravis Achieves Primary Endpoint in China

05 2024.08

First Patient In Achieved in the Global Multicenter Phase III Trial on Telitacicept for Myasthenia Gravis